Why the study?
The potential increase in cardiovascular event risk among patients prescribed macrolide antibiotics has been subject to debate for decades.
Does the administration of macrolide antibiotics increase the risk of cardiovascular events and death compared to non-macrolide use?
Does the administration of macrolide antibiotics increase the risk of cardiovascular events and death compared to non-macrolide use?
Macrolide antibiotics, particularly azithromycin and clarithromycin, are associated with an increased risk of ventricular arrhythmias, sudden cardiac death, and cardiovascular death, highlighting the need for careful electrocardiogram screening in high-risk patients.
Supports macrolide prescribing without CV caution; strengthens evidence against association in largest meta-analysis to date.
Background: The increased risk of cardiovascular events in patients prescribed macrolides has been subject to debate for decades. Methods: Medline, EMBASE databases and ClinicalTrials.gov were searched from inception until August 31, 2022 for studies investigating the link between macrolides and cardiovascular risk. A meta-analysis was performed using a random-effects model. Results: A total of 80 studies involving 39,374,874 patients were included. No association was found between macrolides and all-cause death. However, compared with the non-macrolide group, macrolides were associated with a significantly increased risk of ventricular arrhythmia or sudden cardiac death (VA or SCD) (azithromycin, relative ratio [RR]: 1.53; 95% confidence interval [CI]: 1.19 to 1.97; clarithromycin, RR: 1.52; 95% CI: 1.07 to 2.16). Besides, administration of macrolides was associated with a higher risk of cardiovascular disease (CVD) death (azithromycin, RR: 1.63; 95% CI: 1.17 to 2.27) and a slightly increased risk of myocardial infarction (MI) (azithromycin, RR: 1.08; 95% CI: 1.02 to 1.15). Interestingly, no association was observed between roxithromycin and adverse cardiac outcomes. Increased risk of VA or SCD was observed for recent or current use of macrolides, MI for former use, and CVD death for current use. Conclusion: Administration of macrolide antibiotics and timing of macrolide use are associated with increased risk for SCD or VTA and cardiovascular death, but not all-cause death.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: